Induction in locally advanced uterine cervix carcinoma with cisplatin, paclitaxel, and capecitabine: Response and tolerability.

e16521 Background: Cervix cancer is a public health problem in developing countries, and the locally advanced disease is the most common stage and patiente with complete response after concurrent radiotherapy and cisplatin is low. In this study we use induction chemotherapy in orden to reduce the tumor before radiotherapy administration. Methods: 47 patients with pathological confirmed cervix cancer stage Ib2 to IVa received induction chemotherapy for three cycles with cisplatin, paclitaxel and capecitabine prior to treatment with concurrent chemotherapy-radiotherapy. The primary end points were clinical response rate, pathological response and imaging after induction and secondary end point was safety (NCI toxicity version 3.0). Results: A total of 47 patients found that the average age was 45 years, stage IIB was the most common, squamous histology representing 89.4% of the patients. The clinical response rate was 100%, without disease progression during the period of following. Pathological complete response was 48.9%. The most common hematologic toxicity was anemia (55%) and grade 3 neutropenia (14.8%) but both were manageable, all patients had hand-foot syndrome and alopecia. Neuropathy grade 3 was 12.7%. Conclusions: Induction chemotherapy whith cisplatin, paclitaxel and capecitabine for three cycles prior to standard treatment offers an effective and safety alternative in patients with locally advanced cervical carcinoma.